ATXS Profile
Astria Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapeutics targeting rare and complex allergic and immunological diseases. The company is dedicated to addressing unmet medical needs in the United States through its innovative drug development programs. Astria's approach integrates cutting-edge research and development to create effective treatments for conditions that are often underserved by current therapies.
The company's lead product candidate, STAR-0215, is a monoclonal antibody designed to inhibit plasma kallikrein. This compound is currently in the preclinical development stage and is targeted for the treatment of hereditary angioedema, a rare genetic disorder characterized by recurrent and severe episodes of swelling. STAR-0215 represents a significant advancement in the treatment of this challenging condition, aiming to provide enhanced therapeutic benefits and improved patient outcomes.
Previously known as Catabasis Pharmaceuticals, Inc., the company rebranded to Astria Therapeutics, Inc. in September 2021 to better reflect its strategic focus and evolving portfolio. Founded in 2008 and headquartered in Boston, Massachusetts, Astria Therapeutics operates with a commitment to advancing its therapeutic candidates through rigorous clinical development and bringing innovative solutions to market.
As Astria Therapeutics progresses with its clinical and preclinical programs, it remains focused on its mission to develop groundbreaking treatments for rare and niche diseases. The company's emphasis on addressing specific and complex medical conditions underscores its dedication to improving the quality of life for patients affected by these challenging disorders. With a strong foundation in biopharmaceutical research and a strategic focus on innovative therapies, Astria Therapeutics is well-positioned to make significant contributions to the field of rare disease treatment.
|
